What is Michelson Diagnostics?
Michelson Diagnostics Ltd is a prominent provider of Optical Coherence Tomography (OCT) skin imaging solutions, focusing on high-resolution imaging technology for dermatology and skin research. Their primary product, VivoSight Dx Pro, offers dermatologists, researchers, and clinics a tool for rapid and precise skin health monitoring. Established in 2006, the company's contributions to dermatological imaging have been acknowledged in over 700 peer-reviewed publications, highlighting their impact on the field. The company's commitment to making advanced imaging accessible and user-friendly positions it as a key player in medical technology.
How much funding has Michelson Diagnostics raised?
Michelson Diagnostics has raised a total of $7.1M across 2 funding rounds:
Series A
$3.3M
Series B
$3.8M
Series A (2014): $3.3M with participation from Turner Investments and Catapult Venture Managers Ltd
Series B (2015): $3.8M led by Catapult Venture Managers Ltd and Turner Investments
Key Investors in Michelson Diagnostics
Turner Investments
Turner Investments provides comprehensive financial research and insights across various asset classes, aiming to empower investors with data-driven decision-making tools for navigating market opportunities and risks.
Catapult Venture Managers Ltd
Catapult Venture Managers Ltd specializes in tailored investment solutions, focusing on unlocking entrepreneurial potential and supporting business growth through strategic partnerships and a proven track record.
What's next for Michelson Diagnostics?
With its recent major strategic investment, Michelson Diagnostics is poised for accelerated expansion and further technological development. The company's history of securing substantial capital, including Series A and Series B rounds, suggests a strategic focus on scaling operations, enhancing product capabilities, and broadening market reach. This latest financing is expected to fuel innovation in OCT imaging, potentially leading to new applications in clinical dermatology and research, and solidifying its competitive advantage in the medical imaging landscape. The sustained backing from investors like Turner Investments and Catapult Venture Managers Ltd signals strong market validation and a promising future for the company's growth.
See full Michelson Diagnostics company page
